Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Oral Iloprost for the Precision Chemoprevention of Lung Cancer

NCT05411107 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05411107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Oral Iloprost for the Precision Chemoprevention of Lung Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Withdrawn
Start date
June 1, 2024
Completion date
June 30, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bronchial epithelial dysplasia, chronic obstructive pulmonary disease, lung carcinoma, stage i lung cancer ajcc v8, stage ii lung cancer ajcc v8, tobacco-related carcinoma